GO:1900046 regulation of hemostasis: Biological Process, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1900046 regulation of hemostasis is defined as any process that modulates the frequency, rate or extent of hemostasis, the physiological response that stops bleeding at a site of vascular injury.
• Hemostasis is a tightly coordinated interplay between platelets, coagulation factors, and the vessel wall, and its dysregulation underlies both bleeding and thrombotic disorders [1,2].
• Platelets are central regulators of hemostasis through adhesion, activation, secretion, and aggregation, and they also participate in immunity and inflammation [1,5,6].
• von Willebrand factor (VWF) is a key regulator of hemostasis with emerging functions beyond primary hemostasis, including roles in inflammation and angiogenesis.
• Regulation of hemostasis is relevant to peri-implantational bleeding and menstruation, where local hemostatic balance is hormonally controlled.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models enable causal dissection of hemostasis-regulating genes in platelets, endothelial cells, and hepatocytes [1,2,7].
Description
Hemostasis is the physiological process that seals damaged blood vessels and prevents blood loss while maintaining blood fluidity under normal conditions. The Gene Ontology term GO:1900046, regulation of hemostasis, captures any process that modulates the frequency, rate, or extent of hemostasis, encompassing positive and negative regulatory inputs that fine-tune clot formation and resolution. This term is essential for annotating gene products that control the balance between procoagulant and anticoagulant pathways, platelet reactivity, and vascular repair [1,2].
regulation of hemostasis At A Glance
| GO ID | GO:1900046 |
|---|---|
| GO term | regulation of hemostasis |
| Ontology | biological_process |
| Synonym | none |
| Major function | Modulates the frequency, rate or extent of hemostasis, the physiological response that stops bleeding |
| Related processes | Platelet activation, coagulation cascade, platelet secretion, clot retraction, fibrinolysis [1,2,5] |
| Key cell types | Platelets, endothelial cells, hepatocytes (coagulation factor synthesis) [1,2,4] |
| Disease relevance | Thrombosis, bleeding disorders, von Willebrand disease, peri-implantational bleeding [2,4,8] |
What Is GO:1900046?
GO:1900046 regulation of hemostasis is a biological process that encompasses any molecular or cellular event that modulates the frequency, rate, or extent of hemostasis, the stoppage of bleeding. It includes processes that enhance or suppress platelet adhesion, activation, secretion, aggregation, coagulation cascade activity, and clot stabilization or removal [1,2,5].
Why Is regulation of hemostasis Important in Cell Biology?
Regulation of hemostasis is critically important because imbalances in this process lead to either excessive bleeding or pathological thrombosis, which are major causes of morbidity and mortality worldwide [2,7]. Understanding the regulatory mechanisms that control platelet function, coagulation factor activity, and vascular responses provides a foundation for developing targeted therapies for thrombotic and bleeding disorders [1,2,6].
• Maintains vascular integrity by preventing blood loss after injury while avoiding spontaneous thrombosis.
• Dysregulation causes thrombotic diseases such as myocardial infarction, stroke, and venous thromboembolism [2,6].
• Defects in platelet function or coagulation factors lead to bleeding disorders including von Willebrand disease and hemophilia.
• Platelets, key regulators of hemostasis, also mediate immunity and inflammation, linking hemostasis to inflammatory diseases.
• Peri-implantational hemostasis and menstruation are regulated by local factors, with implications for reproductive medicine.
• Coagulation factor synthesis in the liver is a target for anticoagulant therapy and gene editing approaches [2,7].
• von Willebrand factor has novel functions beyond hemostasis, including roles in angiogenesis and inflammation.
• CRISPR screening can identify novel regulators of hemostasis for therapeutic target discovery [1,2].
What Happens During regulation of hemostasis?
Platelet adhesion and activation
In simple terms: Platelets stick to the injured vessel wall and become activated.
Upon vascular injury, platelets adhere to exposed subendothelial matrix proteins such as collagen and von Willebrand factor (VWF) through glycoprotein receptors, leading to platelet activation [1,4]. This activation triggers intracellular signaling cascades that change platelet shape and promote the release of granular contents [1,5].
Platelet secretion and aggregation
In simple terms: Activated platelets release factors that recruit more platelets and form a plug.
Activated platelets secrete ADP, thromboxane A2, and other mediators from dense and alpha granules, which amplify platelet recruitment and aggregation [1,5]. Platelet secretion is essential for hemostasis and also contributes to wound healing and inflammation.
Coagulation cascade and fibrin formation
In simple terms: Coagulation factors in the blood form a fibrin mesh that stabilizes the platelet plug.
The coagulation cascade, involving intrinsic and extrinsic pathways, culminates in thrombin generation and conversion of fibrinogen to fibrin, which stabilizes the platelet plug [2,7]. This process is tightly regulated by anticoagulant mechanisms to prevent excessive clotting.
Clot resolution and negative regulation
In simple terms: After healing, the clot is broken down to restore blood flow.
Fibrinolysis, mediated by plasmin, degrades the fibrin clot, and negative regulators such as antithrombin and tissue factor pathway inhibitor limit clot propagation [2,7]. Regulation of hemostasis includes these negative feedback mechanisms that maintain blood fluidity.
Key Genes Involved in GO:1900046 regulation of hemostasis
The following genes and proteins are central to the regulation of hemostasis, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| VWF | Mediates platelet adhesion to collagen and carries factor VIII; novel functions in inflammation and angiogenesis | Target for von Willebrand disease and thrombotic disorders |
| F8 | Coagulation factor VIII, cofactor for factor IXa in intrinsic pathway | Hemophilia A gene therapy and editing |
| F9 | Coagulation factor IX, serine protease in intrinsic pathway | Hemophilia B models and gene editing |
| FGA | Fibrinogen alpha chain, precursor of fibrin clot | Dysfibrinogenemia and thrombosis research |
| FGB | Fibrinogen beta chain, component of fibrin | Fibrinogen disorders and clot structure studies |
| FGG | Fibrinogen gamma chain, component of fibrin | Fibrinogen variants and bleeding risk |
| SERPINC1 | Antithrombin, major anticoagulant inhibiting thrombin and factor Xa | Thrombophilia and anticoagulant therapy |
| PROC | Protein C, anticoagulant that inactivates factor Va and VIIIa | Protein C deficiency and thrombosis |
| PROS1 | Protein S, cofactor for protein C | Protein S deficiency and thrombophilia |
| F2 | Prothrombin, precursor of thrombin | Prothrombin mutations and thrombosis risk |
| F5 | Factor V, cofactor in prothrombinase complex; factor V Leiden mutation | Thrombophilia and activated protein C resistance |
| F10 | Factor X, key protease in coagulation cascade | Anticoagulant target and bleeding disorders |
| ITGA2B | Integrin alpha-IIb, platelet fibrinogen receptor subunit | Glanzmann thrombasthenia and antiplatelet therapy |
| ITGB3 | Integrin beta-3, platelet fibrinogen receptor subunit | Glanzmann thrombasthenia and platelet function studies |
| GP1BA | Glycoprotein Ib alpha, platelet receptor for VWF | Bernard-Soulier syndrome and platelet adhesion |
| P2RY12 | P2Y12 receptor for ADP, amplifies platelet activation | Target of antiplatelet drugs like clopidogrel |
| TBXA2R | Thromboxane A2 receptor, promotes platelet aggregation | Aspirin response and platelet function |
How Is regulation of hemostasis Regulated?
Regulation of hemostasis is controlled by a balance of procoagulant and anticoagulant factors, including thrombin, antithrombin, protein C, and protein S [2,7]. Platelet reactivity is modulated by signaling pathways downstream of G-protein-coupled receptors such as P2Y12 and thromboxane A2 receptor, which amplify or dampen platelet activation. Additionally, local factors in the endometrium regulate peri-implantational hemostasis and menstruation, involving hormonal control of vascular remodeling.
regulation of hemostasis and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| VWF | Von Willebrand disease, thrombotic thrombocytopenic purpura | Knockout and point-mutation models in endothelial cells and megakaryocytes |
| F8 | Hemophilia A | Knockout and knock-in models in hepatocytes and iPSCs |
| F9 | Hemophilia B | Knockout and knock-in models in hepatocytes |
| F5 | Factor V Leiden thrombophilia | Point-mutation knock-in models in hepatocytes |
| ITGA2B | Glanzmann thrombasthenia | Knockout models in megakaryocytic cell lines |
Thrombotic disorders
Dysregulated hemostasis contributes to arterial and venous thrombosis, including myocardial infarction, ischemic stroke, and deep vein thrombosis [2,6]. Platelets are key mediators of thrombosis, and antiplatelet therapies targeting P2Y12 and thromboxane pathways are mainstays of treatment [1,6].
Bleeding disorders
Defects in platelet adhesion, aggregation, or coagulation factors cause bleeding disorders such as von Willebrand disease, hemophilia A and B, and Glanzmann thrombasthenia [2,4]. Von Willebrand factor mutations lead to von Willebrand disease, the most common inherited bleeding disorder.
Inflammation and immunity
Platelets link hemostasis with inflammation and immunity, contributing to conditions such as atherosclerosis and sepsis. von Willebrand factor has novel functions in inflammation and angiogenesis beyond hemostasis.
Reproductive biology
Peri-implantational hemostasis and menstruation are regulated by local endometrial factors, and disturbances can affect fertility and menstrual bleeding.
From regulation of hemostasis-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene affect platelet aggregation? | Knockout in megakaryocytic cell lines or primary megakaryocytes |
| Does a specific point mutation in F5 cause activated protein C resistance? | Point-mutation knock-in in hepatocyte-like cells |
| Can a therapeutic transgene restore coagulation factor secretion? | Knock-in of corrective cDNA in hepatocytes |
| Does overexpression of VWF increase platelet adhesion under flow? | Overexpression in endothelial cells |
| Which genes regulate platelet secretion? | CRISPR library screening in megakaryocytic cells |
| Does a tagged coagulation factor localize correctly? | Tagged knock-in in hepatocytes |
How to Study the regulation of hemostasis Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Platelet aggregometry | Platelet aggregation in response to agonists | Assessing platelet function in knockout models |
| Flow cytometry | Platelet activation markers and receptor expression | Evaluating platelet activation states |
| Thrombin generation assay | Overall coagulation potential | Screening for coagulation factor defects |
| ELISA | VWF, fibrinogen, and factor levels | Quantifying hemostatic proteins in plasma |
| CRISPR knockout screening | Gene essentiality for platelet function | Discovery of novel hemostasis regulators |
| RNA-seq | Transcriptomic changes in platelets or endothelial cells | Identifying regulatory pathways |
| Proteomics | Protein composition of platelets or clots | Mapping hemostatic protein networks |
Platelet function assays
Platelet aggregation, secretion, and adhesion assays are used to measure the functional consequences of genetic perturbations in hemostasis regulators [1,5].
Coagulation assays
PT, aPTT, and thrombin generation assays assess the activity of coagulation factors and the overall hemostatic balance in plasma or cell culture media [2,7].
CRISPR screening
Genome-wide CRISPR knockout or activation screens in megakaryocytic cell lines can identify novel regulators of platelet function and hemostasis [1,2].
Animal models
Mouse models of hemostasis, including knockout and knock-in strains, are used to study bleeding and thrombosis phenotypes in vivo [2,7].
How CRISPR Can Be Used to Study GO:1900046 regulation of hemostasis
Knockout
CRISPR knockout of candidate genes in megakaryocytic cell lines or hepatocytes can determine whether a gene is required for platelet function or coagulation factor production [1,2].
Point Mutation
Point mutations, such as factor V Leiden, can be introduced into cell models to study their impact on hemostasis and resistance to anticoagulant pathways.
Knock-in
Knock-in of disease-associated variants or tagged proteins allows precise modeling of hemostatic disorders and tracking of protein localization [2,4].
Overexpression
Overexpression of hemostasis regulators such as VWF in endothelial cells can reveal gain-of-function effects on platelet adhesion and thrombosis.
How EDITGENE Supports regulation of hemostasis Research
Researchers studying regulation of hemostasis-related genes often need to determine whether a candidate gene is causally involved in platelet function, coagulation, or vascular repair. EDITGENE provides CRISPR-based cell model services to enable such causal studies.
Contact EDITGENE today to design your custom CRISPR model for regulation of hemostasis research.
Frequently Asked Questions About regulation of hemostasis
What is GO:1900046 regulation of hemostasis?
GO:1900046 is a Gene Ontology biological process term defined as any process that modulates the frequency, rate or extent of hemostasis, the physiological response that stops bleeding.
What genes are involved in regulation of hemostasis?
Key genes include VWF, F8, F9, FGA, FGB, FGG, SERPINC1, PROC, PROS1, F2, F5, F10, ITGA2B, ITGB3, GP1BA, P2RY12, and TBXA2R [1,2,4].
How is hemostasis regulated?
Hemostasis is regulated by a balance of platelet activation, coagulation cascade activity, and anticoagulant pathways involving antithrombin, protein C, and protein S [2,7].
What diseases are linked to dysregulated hemostasis?
Dysregulated hemostasis is linked to thrombosis, bleeding disorders such as von Willebrand disease and hemophilia, and inflammatory conditions [2,4,6].
What is the role of platelets in hemostasis?
Platelets adhere to injured vessels, become activated, secrete mediators, and aggregate to form a plug, and they also participate in immunity and inflammation [1,5,6].
How can CRISPR be used to study regulation of hemostasis?
CRISPR knockout, point mutation, knock-in, and overexpression models in megakaryocytic, endothelial, and hepatic cells enable causal studies of hemostasis genes [1,2,4].
What is von Willebrand factor's role in hemostasis?
VWF mediates platelet adhesion to collagen and carries factor VIII, and it has novel functions in inflammation and angiogenesis.
What are the main stages of hemostasis?
The main stages are platelet adhesion and activation, platelet secretion and aggregation, coagulation cascade and fibrin formation, and clot resolution [1,2,5,7].
How is peri-implantational hemostasis regulated?
Peri-implantational hemostasis and menstruation are regulated by local endometrial factors, with implications for reproductive medicine.
What research methods are used to study regulation of hemostasis?
Methods include platelet aggregometry, thrombin generation assays, ELISA, CRISPR screening, RNA-seq, and proteomics [1,2,4,5,6].
Conclusion
GO:1900046 regulation of hemostasis is a fundamental biological process that controls the balance between bleeding and clotting through the coordinated actions of platelets, coagulation factors, and vascular cells [1,2,7]. Understanding its regulatory mechanisms is essential for developing therapies for thrombotic and bleeding disorders, and CRISPR-based models provide powerful tools for causal gene discovery in this field [1,2,4].
References
- 1. Holinstat M. 2017. Normal platelet function.. Cancer Metastasis Rev 36(2):195-198 PMID: 28667366
- 2. Sang Y et al.. 2021. Interplay between platelets and coagulation.. Blood Rev 46:100733 PMID: 32682574
- 4. Atiq F et al.. 2024. Novel functions for von Willebrand factor.. Blood 144(12):1247-1256 PMID: 38728426
- 5. Golebiewska EM et al.. 2015. Platelet secretion: From haemostasis to wound healing and beyond.. Blood Rev 29(3):153-62 PMID: 25468720
- 6. Koupenova M et al.. 2018. Circulating Platelets as Mediators of Immunity, Inflammation, and Thrombosis.. Circ Res 122(2):337-351 PMID: 29348254
- 7. Versteeg HH et al.. 2013. New fundamentals in hemostasis.. Physiol Rev 93(1):327-58 PMID: 23303912
- 8. Lockwood CJ et al.. 1996. A biological model for the regulation of peri-implantational hemostasis and menstruation.. J Soc Gynecol Investig 3(4):159-65 PMID: 8796825
